EcoDrugPlus

C-C Motif Chemokine Receptor 1

Ensembl ID : ENSBMSG00010019609
Gene Symbol: CCR1
1 Cross references
158 Possible Orthologues:

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSBMSG00010019624
Gene Symbol: CCR2
1 Cross references
150 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSBMSG00010011298
Gene Symbol: CCR4
1 Cross references
113 Possible Orthologues:

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSBMSG00010019633
Gene Symbol: CCR5
1 Cross references
152 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSBMSG00010019542
Gene Symbol: CCR9
1 Cross references
265 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSBMSG00010006922
Gene Symbol: CXCL8
1 Cross references
179 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSBMSG00010001344
Gene Symbol: CXCR4
1 Cross references
218 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSBMSG00010007097
Gene Symbol: CFTR
1 Cross references
217 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSBMSG00010011892
Gene Symbol: DNMT1
1 Cross references
212 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSBMSG00010021001
Gene Symbol: TOP1
1 Cross references
273 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSBMSG00010015282
Gene Symbol: TOP2A
1 Cross references
206 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSBMSG00010001287
Gene Symbol: TOP2B
1 Cross references
210 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).